GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kaken Pharmaceutical Co Ltd (OTCPK:KKPCF) » Definitions » Piotroski F-Score

KKPCF (Kaken Pharmaceutical Co) Piotroski F-Score : 5 (As of Dec. 14, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Kaken Pharmaceutical Co Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Kaken Pharmaceutical Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Kaken Pharmaceutical Co's Piotroski F-Score or its related term are showing as below:

KKPCF' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 9
Current: 5

During the past 13 years, the highest Piotroski F-Score of Kaken Pharmaceutical Co was 9. The lowest was 4. And the median was 6.


Kaken Pharmaceutical Co Piotroski F-Score Historical Data

The historical data trend for Kaken Pharmaceutical Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kaken Pharmaceutical Co Piotroski F-Score Chart

Kaken Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.00 6.00 7.00 5.00 5.00

Kaken Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 5.00 - -

Competitive Comparison of Kaken Pharmaceutical Co's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kaken Pharmaceutical Co's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Kaken Pharmaceutical Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was $53.6 Mil.
Cash Flow from Operations was $17.2 Mil.
Revenue was $480.9 Mil.
Gross Profit was $257.2 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was (1244.371 + 1145.539) / 2 = $1194.955 Mil.
Total Assets at the begining of this year (Mar23) was $1,244.4 Mil.
Long-Term Debt & Capital Lease Obligation was $0.0 Mil.
Total Current Assets was $714.0 Mil.
Total Current Liabilities was $127.0 Mil.
Net Income was $40.7 Mil.

Revenue was $546.0 Mil.
Gross Profit was $295.9 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was (1393.023 + 1244.371) / 2 = $1318.697 Mil.
Total Assets at the begining of last year (Mar22) was $1,393.0 Mil.
Long-Term Debt & Capital Lease Obligation was $0.0 Mil.
Total Current Assets was $822.2 Mil.
Total Current Liabilities was $155.9 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Kaken Pharmaceutical Co's current Net Income (TTM) was 53.6. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Kaken Pharmaceutical Co's current Cash Flow from Operations (TTM) was 17.2. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=53.565/1244.371
=0.04304584

ROA (Last Year)=Net Income/Total Assets (Mar22)
=40.699/1393.023
=0.02921632

Kaken Pharmaceutical Co's return on assets of this year was 0.04304584. Kaken Pharmaceutical Co's return on assets of last year was 0.02921632. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Kaken Pharmaceutical Co's current Net Income (TTM) was 53.6. Kaken Pharmaceutical Co's current Cash Flow from Operations (TTM) was 17.2. ==> 17.2 <= 53.6 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=0/1194.955
=0

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=0/1318.697
=0

Kaken Pharmaceutical Co's gearing of this year was 0. Kaken Pharmaceutical Co's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=714.023/126.98
=5.62311388

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=822.232/155.898
=5.27416644

Kaken Pharmaceutical Co's current ratio of this year was 5.62311388. Kaken Pharmaceutical Co's current ratio of last year was 5.27416644. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Kaken Pharmaceutical Co's number of shares in issue this year was 37.737. Kaken Pharmaceutical Co's number of shares in issue last year was 37.571. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=257.238/480.875
=0.53493735

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=295.928/546.025
=0.54196786

Kaken Pharmaceutical Co's gross margin of this year was 0.53493735. Kaken Pharmaceutical Co's gross margin of last year was 0.54196786. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=480.875/1244.371
=0.38644022

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=546.025/1393.023
=0.39197127

Kaken Pharmaceutical Co's asset turnover of this year was 0.38644022. Kaken Pharmaceutical Co's asset turnover of last year was 0.39197127. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+0+1+1+0+0+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Kaken Pharmaceutical Co has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Kaken Pharmaceutical Co  (OTCPK:KKPCF) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Kaken Pharmaceutical Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Kaken Pharmaceutical Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Kaken Pharmaceutical Co Business Description

Traded in Other Exchanges
Address
28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650
Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Kaken Pharmaceutical Co Headlines

No Headlines